[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fslHV6axK0zxGdmutTojmR7Y1CObfTrc3tbtii29ub2s":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":83,"rows":90},"Fondation Ophtalmologique Adolphe de Rothschild",[4],312,false,82,11,54416,13,276,[14,17,20,23,25,27,29,32],{"name":15,"count":16},"Multiple Sclerosis",15,{"name":18,"count":19},"Epilepsy",9,{"name":21,"count":22},"Stroke",7,{"name":24,"count":22},"Optic Neuritis",{"name":26,"count":22},"Cataract",{"name":28,"count":22},"Ischemic Stroke",{"name":30,"count":31},"Myopia",5,{"name":33,"count":31},"Acute Stroke",[35,40,45,50,54,59,64,69,73,78],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05062031","Myopia Control in Children: Comparison of Defocus Incorporated Multiple Segments® Lenses Versus Atropine 0.05% Eyedrops","2026-02","Atropine 0.05% eyedrops",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04772963","Genetics of Central Nervous System Arteriovenous Malformations (GENE-MAV)","2026-03","blood sample",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT02890641","Genetic and Electrophysiologic Study in Focal Drug-resistant Epilepsies","2026-12","Sampling of blood, frozen resected tissues, and cerebrospinal fluid",{"nctId":51,"briefTitle":52,"date":53,"intervention":44},"NCT03283852","Identifying New Genetic Causes to Development Disorders","2027-02-21",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06264531","Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations","2028-01-15","Bevacizumab",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT06723717","Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months","2028-03","Daily infusion of dornase alfa",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT06342544","Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.","2028-06","immediate treatment with corticosteroids",{"nctId":70,"briefTitle":71,"date":67,"intervention":72},"NCT06585384","Safety of a Strategy Combining Etanercept Administration With Repeated Contrast Ultrasound in Patients With Alzheimer's Disease","etanercept and repeated contrast ultrasound",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT07318870","Efficacy of Probenecid on Cluster Seizures During Anti Seizure Medication Withdrawal in Presurgical Focal Epilepsy Video-EEG Monitoring","2029-02","Probenecid",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT07329569","Treatment of Severe Ocular Chemical Burns by Subconjunctival Injection of Allogeneic Mesenchymal Stem Cells: An Open-Label, Single-Arm, Multicenter Phase II Trial","2029-09","Subconjunctival injection of 1 mL with 5 million allogeneic BM-MSCs; one repeat within 21 days.",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,119,146,170,193,211,233,256,278,299,320,352,373,395,422,440,466,490,514,540,558,585,611,637,666,693,711,729,754,790,816,843,868,892,918,943,967,993,1018],{"intervention":92,"totalTrials":93,"cells":94},"glenzocimab",1,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":115,"NA":117},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[],{"trials":101,"activeCount":97},[],{"trials":103,"activeCount":93,"soonestReadout":109},[104],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":114},"NCT06437431","Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy","NOT_YET_RECRUITING",[86,87],"2030-10","2026-09",304,[113],"Acute Ischemic Stroke",[92],{"trials":116,"activeCount":97},[],{"trials":118,"activeCount":97},[],{"intervention":120,"totalTrials":93,"cells":121},"Cangrelor",{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":128,"PHASE4":142,"NA":144},{"trials":123,"activeCount":97},[],{"trials":125,"activeCount":97},[],{"trials":127,"activeCount":97},[],{"trials":129,"activeCount":93,"soonestReadout":135},[130],{"nctId":131,"briefTitle":132,"status":133,"phases":134,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":141},"NCT04667078","REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts","RECRUITING",[87],"2030-03-01","2030-09-01","2022-03-02",368,[140],"Acute Ischemia",[120],{"trials":143,"activeCount":97},[],{"trials":145,"activeCount":97},[],{"intervention":147,"totalTrials":93,"cells":148},"Ocrelizumab Injection [Ocrevus]",{"EARLY_PHASE1":149,"PHASE1":151,"PHASE2":153,"PHASE3":155,"PHASE4":166,"NA":168},{"trials":150,"activeCount":97},[],{"trials":152,"activeCount":97},[],{"trials":154,"activeCount":97},[],{"trials":156,"activeCount":93,"soonestReadout":161},[157],{"nctId":158,"briefTitle":159,"status":133,"phases":160,"primaryCompletion":161,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":165},"NCT05999604","Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial",[87],"2029-11","2023-11-09",244,[15],[147,147],{"trials":167,"activeCount":97},[],{"trials":169,"activeCount":97},[],{"intervention":68,"totalTrials":93,"cells":171},{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":176,"PHASE3":178,"PHASE4":189,"NA":191},{"trials":173,"activeCount":97},[],{"trials":175,"activeCount":97},[],{"trials":177,"activeCount":97},[],{"trials":179,"activeCount":93,"soonestReadout":67},[180],{"nctId":65,"briefTitle":66,"status":133,"phases":181,"primaryCompletion":67,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":187},[87],"2029-06","2025-04-29",128,[186],"Ocular Myasthenia Gravis",[68,188],"addition of rituximab if recurrence",{"trials":190,"activeCount":97},[],{"trials":192,"activeCount":97},[],{"intervention":188,"totalTrials":93,"cells":194},{"EARLY_PHASE1":195,"PHASE1":197,"PHASE2":199,"PHASE3":201,"PHASE4":207,"NA":209},{"trials":196,"activeCount":97},[],{"trials":198,"activeCount":97},[],{"trials":200,"activeCount":97},[],{"trials":202,"activeCount":93,"soonestReadout":67},[203],{"nctId":65,"briefTitle":66,"status":133,"phases":204,"primaryCompletion":67,"completion":182,"start":183,"enrollment":184,"conditions":205,"interventions":206},[87],[186],[68,188],{"trials":208,"activeCount":97},[],{"trials":210,"activeCount":97},[],{"intervention":58,"totalTrials":93,"cells":212},{"EARLY_PHASE1":213,"PHASE1":215,"PHASE2":217,"PHASE3":219,"PHASE4":229,"NA":231},{"trials":214,"activeCount":97},[],{"trials":216,"activeCount":97},[],{"trials":218,"activeCount":97},[],{"trials":220,"activeCount":93,"soonestReadout":57},[221],{"nctId":55,"briefTitle":56,"status":133,"phases":222,"primaryCompletion":57,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":228},[86,87],"2029-01-15","2026-01-16",54,[227],"Cerebral AV Malformation",[58],{"trials":230,"activeCount":97},[],{"trials":232,"activeCount":97},[],{"intervention":63,"totalTrials":93,"cells":234},{"EARLY_PHASE1":235,"PHASE1":237,"PHASE2":239,"PHASE3":250,"PHASE4":252,"NA":254},{"trials":236,"activeCount":97},[],{"trials":238,"activeCount":97},[],{"trials":240,"activeCount":93,"soonestReadout":62},[241],{"nctId":60,"briefTitle":61,"status":133,"phases":242,"primaryCompletion":62,"completion":243,"start":244,"enrollment":111,"conditions":245,"interventions":249},[86],"2028-09","2025-09-26",[246,247,248],"Ruptured Aneurysm of Intracranial Artery","SAH (Subarachnoid Hemorrhage)","Delayed Cerebral Ischemia",[63],{"trials":251,"activeCount":97},[],{"trials":253,"activeCount":97},[],{"trials":255,"activeCount":97},[],{"intervention":82,"totalTrials":93,"cells":257},{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":262,"PHASE3":272,"PHASE4":274,"NA":276},{"trials":259,"activeCount":97},[],{"trials":261,"activeCount":97},[],{"trials":263,"activeCount":93,"soonestReadout":81},[264],{"nctId":79,"briefTitle":80,"status":107,"phases":265,"primaryCompletion":81,"completion":266,"start":43,"enrollment":267,"conditions":268,"interventions":271},[86],"2030-04",21,[269,270],"Chemical Burns","Ocular Burns",[82],{"trials":273,"activeCount":97},[],{"trials":275,"activeCount":97},[],{"trials":277,"activeCount":97},[],{"intervention":77,"totalTrials":93,"cells":279},{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":293,"PHASE4":295,"NA":297},{"trials":281,"activeCount":97},[],{"trials":283,"activeCount":97},[],{"trials":285,"activeCount":93,"soonestReadout":76},[286],{"nctId":74,"briefTitle":75,"status":107,"phases":287,"primaryCompletion":76,"completion":76,"start":288,"enrollment":289,"conditions":290,"interventions":292},[86],"2026-01",600,[291],"Focal Epilepsy",[77],{"trials":294,"activeCount":97},[],{"trials":296,"activeCount":97},[],{"trials":298,"activeCount":97},[],{"intervention":72,"totalTrials":93,"cells":300},{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":312,"PHASE3":314,"PHASE4":316,"NA":318},{"trials":302,"activeCount":97},[],{"trials":304,"activeCount":93,"soonestReadout":67},[305],{"nctId":70,"briefTitle":71,"status":133,"phases":306,"primaryCompletion":67,"completion":307,"start":308,"enrollment":31,"conditions":309,"interventions":311},[85],"2028-12","2025-04-15",[310],"Alzheimer Disease",[72],{"trials":313,"activeCount":97},[],{"trials":315,"activeCount":97},[],{"trials":317,"activeCount":97},[],{"trials":319,"activeCount":97},[],{"intervention":44,"totalTrials":321,"cells":322},2,{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":331,"NA":333},{"trials":324,"activeCount":97},[],{"trials":326,"activeCount":97},[],{"trials":328,"activeCount":97},[],{"trials":330,"activeCount":97},[],{"trials":332,"activeCount":97},[],{"trials":334,"activeCount":321,"soonestReadout":43},[335,344],{"nctId":51,"briefTitle":52,"status":133,"phases":336,"primaryCompletion":53,"completion":53,"start":337,"enrollment":338,"conditions":339,"interventions":343},[],"2017-02-21",1100,[340,341,342],"Disorders of Sex Development","Growth Disorders","Puberty Disorders",[44],{"nctId":41,"briefTitle":42,"status":133,"phases":345,"primaryCompletion":43,"completion":346,"start":347,"enrollment":348,"conditions":349,"interventions":351},[],"2027-03","2022-02-17",300,[350],"Arteriovenous Malformations",[44],{"intervention":39,"totalTrials":93,"cells":353},{"EARLY_PHASE1":354,"PHASE1":356,"PHASE2":358,"PHASE3":360,"PHASE4":362,"NA":364},{"trials":355,"activeCount":97},[],{"trials":357,"activeCount":97},[],{"trials":359,"activeCount":97},[],{"trials":361,"activeCount":97},[],{"trials":363,"activeCount":97},[],{"trials":365,"activeCount":93,"soonestReadout":38},[366],{"nctId":36,"briefTitle":37,"status":367,"phases":368,"primaryCompletion":38,"completion":38,"start":369,"enrollment":370,"conditions":371,"interventions":372},"ACTIVE_NOT_RECRUITING",[89],"2021-10-19",242,[30],[39],{"intervention":49,"totalTrials":93,"cells":374},{"EARLY_PHASE1":375,"PHASE1":377,"PHASE2":379,"PHASE3":381,"PHASE4":383,"NA":385},{"trials":376,"activeCount":97},[],{"trials":378,"activeCount":97},[],{"trials":380,"activeCount":97},[],{"trials":382,"activeCount":97},[],{"trials":384,"activeCount":97},[],{"trials":386,"activeCount":93,"soonestReadout":48},[387],{"nctId":46,"briefTitle":47,"status":133,"phases":388,"primaryCompletion":48,"completion":389,"start":390,"enrollment":391,"conditions":392,"interventions":394},[],"2031-12","2015-12-17",450,[393],"Drug-resistant Focal Epilepsies in Pediatric Population",[49],{"intervention":396,"totalTrials":93,"cells":397},"injection of placebo",{"EARLY_PHASE1":398,"PHASE1":400,"PHASE2":402,"PHASE3":404,"PHASE4":406,"NA":420},{"trials":399,"activeCount":97},[],{"trials":401,"activeCount":97},[],{"trials":403,"activeCount":97},[],{"trials":405,"activeCount":97},[],{"trials":407,"activeCount":97},[408],{"nctId":409,"briefTitle":410,"status":411,"phases":412,"primaryCompletion":413,"start":414,"enrollment":415,"conditions":416,"interventions":418},"NCT02004015","Assessment Study of the Effect of NMBA on Bowel Peristalsis","TERMINATED",[88],"2015-04","2013-11",50,[417],"Physiopathology",[396,419],"injection of NMBA",{"trials":421,"activeCount":97},[],{"intervention":419,"totalTrials":93,"cells":423},{"EARLY_PHASE1":424,"PHASE1":426,"PHASE2":428,"PHASE3":430,"PHASE4":432,"NA":438},{"trials":425,"activeCount":97},[],{"trials":427,"activeCount":97},[],{"trials":429,"activeCount":97},[],{"trials":431,"activeCount":97},[],{"trials":433,"activeCount":97},[434],{"nctId":409,"briefTitle":410,"status":411,"phases":435,"primaryCompletion":413,"start":414,"enrollment":415,"conditions":436,"interventions":437},[88],[417],[396,419],{"trials":439,"activeCount":97},[],{"intervention":441,"totalTrials":93,"cells":442},"Paracetamol",{"EARLY_PHASE1":443,"PHASE1":445,"PHASE2":447,"PHASE3":449,"PHASE4":451,"NA":464},{"trials":444,"activeCount":97},[],{"trials":446,"activeCount":97},[],{"trials":448,"activeCount":97},[],{"trials":450,"activeCount":97},[],{"trials":452,"activeCount":97},[453],{"nctId":454,"briefTitle":455,"status":456,"phases":457,"primaryCompletion":458,"completion":458,"start":459,"enrollment":460,"conditions":461,"interventions":463},"NCT03648021","The Effect of Paracetamol on Brain Temperature","COMPLETED",[88],"2022-05-26","2018-05-03",100,[462],"Brain Injuries",[441],{"trials":465,"activeCount":97},[],{"intervention":467,"totalTrials":93,"cells":468},"Propofol",{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":473,"PHASE3":475,"PHASE4":477,"NA":488},{"trials":470,"activeCount":97},[],{"trials":472,"activeCount":97},[],{"trials":474,"activeCount":97},[],{"trials":476,"activeCount":97},[],{"trials":478,"activeCount":97},[479],{"nctId":480,"briefTitle":481,"status":456,"phases":482,"primaryCompletion":337,"completion":337,"start":483,"enrollment":484,"conditions":485,"interventions":487},"NCT02771912","Patient-controlled Sedation With Propofol During Cataract Surgery Under Topical Anesthesia",[88],"2016-07",60,[486],"Sedation",[467],{"trials":489,"activeCount":97},[],{"intervention":491,"totalTrials":93,"cells":492},"Dimethyl fumarate",{"EARLY_PHASE1":493,"PHASE1":495,"PHASE2":497,"PHASE3":499,"PHASE4":501,"NA":512},{"trials":494,"activeCount":97},[],{"trials":496,"activeCount":97},[],{"trials":498,"activeCount":97},[],{"trials":500,"activeCount":97},[],{"trials":502,"activeCount":97},[503],{"nctId":504,"briefTitle":505,"status":411,"phases":506,"primaryCompletion":507,"completion":507,"start":508,"enrollment":9,"conditions":509,"interventions":511},"NCT02901106","Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate",[88],"2017-10-17","2017-05-23",[510],"Multiple Sclerosis, Relapsing-Remitting",[491],{"trials":513,"activeCount":97},[],{"intervention":515,"totalTrials":93,"cells":516},"Prothrombin Complex Concentrate",{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":523,"PHASE4":525,"NA":538},{"trials":518,"activeCount":97},[],{"trials":520,"activeCount":97},[],{"trials":522,"activeCount":97},[],{"trials":524,"activeCount":97},[],{"trials":526,"activeCount":97},[527],{"nctId":528,"briefTitle":529,"status":456,"phases":530,"primaryCompletion":531,"completion":531,"start":532,"enrollment":533,"conditions":534,"interventions":536},"NCT02777424","CPP Versus PFC to Correct Coagulation Disorders in Adult Neurosurgical Patients",[88],"2019-03-27","2016-01-21",18,[535],"Intracranial Hemorrhages",[515,537],"Fresh Frozen Plasma",{"trials":539,"activeCount":97},[],{"intervention":537,"totalTrials":93,"cells":541},{"EARLY_PHASE1":542,"PHASE1":544,"PHASE2":546,"PHASE3":548,"PHASE4":550,"NA":556},{"trials":543,"activeCount":97},[],{"trials":545,"activeCount":97},[],{"trials":547,"activeCount":97},[],{"trials":549,"activeCount":97},[],{"trials":551,"activeCount":97},[552],{"nctId":528,"briefTitle":529,"status":456,"phases":553,"primaryCompletion":531,"completion":531,"start":532,"enrollment":533,"conditions":554,"interventions":555},[88],[535],[515,537],{"trials":557,"activeCount":97},[],{"intervention":559,"totalTrials":93,"cells":560},"Rocuronium",{"EARLY_PHASE1":561,"PHASE1":563,"PHASE2":565,"PHASE3":567,"PHASE4":569,"NA":583},{"trials":562,"activeCount":97},[],{"trials":564,"activeCount":97},[],{"trials":566,"activeCount":97},[],{"trials":568,"activeCount":97},[],{"trials":570,"activeCount":97},[571],{"nctId":572,"briefTitle":573,"status":574,"phases":575,"primaryCompletion":576,"completion":577,"start":578,"enrollment":579,"conditions":580,"interventions":582},"NCT02589691","Neuromuscular-Blocking Agents and Hypoxemia During Intubation in Infants (ROC-HYPOX)","UNKNOWN",[88],"2024-12-23","2025-12-23","2015-12-23",412,[581],"Hypoxemia",[559],{"trials":584,"activeCount":97},[],{"intervention":586,"totalTrials":93,"cells":587},"Dornase Alfa Inhalation Solution [Pulmozyme]",{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":594,"PHASE4":607,"NA":609},{"trials":589,"activeCount":97},[],{"trials":591,"activeCount":97},[],{"trials":593,"activeCount":97},[],{"trials":595,"activeCount":97},[596],{"nctId":597,"briefTitle":598,"status":411,"phases":599,"primaryCompletion":600,"completion":600,"start":601,"enrollment":602,"conditions":603,"interventions":606},"NCT04355364","Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE)",[87],"2021-12-20","2020-04-21",77,[604,605],"COVID-19","Acute Respiratory Distress Syndrome",[586],{"trials":608,"activeCount":97},[],{"trials":610,"activeCount":97},[],{"intervention":612,"totalTrials":93,"cells":613},"Anti-VEGF injections of bevacizumab",{"EARLY_PHASE1":614,"PHASE1":616,"PHASE2":618,"PHASE3":620,"PHASE4":633,"NA":635},{"trials":615,"activeCount":97},[],{"trials":617,"activeCount":97},[],{"trials":619,"activeCount":97},[],{"trials":621,"activeCount":97},[622],{"nctId":623,"briefTitle":624,"status":411,"phases":625,"primaryCompletion":626,"completion":627,"start":628,"enrollment":533,"conditions":629,"interventions":632},"NCT03940690","Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease",[87],"2023-06-06","2023-10-13","2019-10-24",[630,631],"Retinal Telangiectasis","Coats Disease",[612],{"trials":634,"activeCount":97},[],{"trials":636,"activeCount":97},[],{"intervention":638,"totalTrials":93,"cells":639},"Budesonide Nasal",{"EARLY_PHASE1":640,"PHASE1":642,"PHASE2":644,"PHASE3":646,"PHASE4":662,"NA":664},{"trials":641,"activeCount":97},[],{"trials":643,"activeCount":97},[],{"trials":645,"activeCount":97},[],{"trials":647,"activeCount":97},[648],{"nctId":649,"briefTitle":650,"status":456,"phases":651,"primaryCompletion":652,"completion":653,"start":654,"enrollment":655,"conditions":656,"interventions":661},"NCT04361474","Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity",[87],"2020-11-24","2021-06-25","2020-05-18",120,[657,658,659,660],"Budesonide","Olfaction Disorders","SARS-CoV-2","Anosmia",[638],{"trials":663,"activeCount":97},[],{"trials":665,"activeCount":97},[],{"intervention":667,"totalTrials":93,"cells":668},"Clopidogrel",{"EARLY_PHASE1":669,"PHASE1":671,"PHASE2":673,"PHASE3":675,"PHASE4":689,"NA":691},{"trials":670,"activeCount":97},[],{"trials":672,"activeCount":97},[],{"trials":674,"activeCount":97},[],{"trials":676,"activeCount":97},[677],{"nctId":678,"briefTitle":679,"status":456,"phases":680,"primaryCompletion":681,"completion":682,"start":683,"enrollment":460,"conditions":684,"interventions":686},"NCT02675205","Ticagrelor vs Clopidogrel for Platelet Inhibition in Stenting for Cerebral Aneurysm",[87],"2020-07","2020-12","2015-12",[685],"Cerebral Aneurysm",[667,687,688],"Ticagrelor","aspirin",{"trials":690,"activeCount":97},[],{"trials":692,"activeCount":97},[],{"intervention":687,"totalTrials":93,"cells":694},{"EARLY_PHASE1":695,"PHASE1":697,"PHASE2":699,"PHASE3":701,"PHASE4":707,"NA":709},{"trials":696,"activeCount":97},[],{"trials":698,"activeCount":97},[],{"trials":700,"activeCount":97},[],{"trials":702,"activeCount":97},[703],{"nctId":678,"briefTitle":679,"status":456,"phases":704,"primaryCompletion":681,"completion":682,"start":683,"enrollment":460,"conditions":705,"interventions":706},[87],[685],[667,687,688],{"trials":708,"activeCount":97},[],{"trials":710,"activeCount":97},[],{"intervention":688,"totalTrials":93,"cells":712},{"EARLY_PHASE1":713,"PHASE1":715,"PHASE2":717,"PHASE3":719,"PHASE4":725,"NA":727},{"trials":714,"activeCount":97},[],{"trials":716,"activeCount":97},[],{"trials":718,"activeCount":97},[],{"trials":720,"activeCount":97},[721],{"nctId":678,"briefTitle":679,"status":456,"phases":722,"primaryCompletion":681,"completion":682,"start":683,"enrollment":460,"conditions":723,"interventions":724},[87],[685],[667,687,688],{"trials":726,"activeCount":97},[],{"trials":728,"activeCount":97},[],{"intervention":730,"totalTrials":93,"cells":731},"Administration of dornase alfa",{"EARLY_PHASE1":732,"PHASE1":734,"PHASE2":736,"PHASE3":748,"PHASE4":750,"NA":752},{"trials":733,"activeCount":97},[],{"trials":735,"activeCount":97},[],{"trials":737,"activeCount":97},[738],{"nctId":739,"briefTitle":740,"status":456,"phases":741,"primaryCompletion":742,"completion":743,"start":744,"enrollment":745,"conditions":746,"interventions":747},"NCT04785066","Efficacy of Pulmozyme® on Arterial Recanalization in Post-thrombectomy Patients Managed for Ischemic Stroke (NETs-target)",[86],"2025-08-18","2025-10-30","2022-08-19",39,[28],[730],{"trials":749,"activeCount":97},[],{"trials":751,"activeCount":97},[],{"trials":753,"activeCount":97},[],{"intervention":755,"totalTrials":321,"cells":756},"Apomorphine",{"EARLY_PHASE1":757,"PHASE1":759,"PHASE2":761,"PHASE3":763,"PHASE4":765,"NA":777},{"trials":758,"activeCount":97},[],{"trials":760,"activeCount":97},[],{"trials":762,"activeCount":97},[],{"trials":764,"activeCount":97},[],{"trials":766,"activeCount":97},[767],{"nctId":768,"briefTitle":769,"status":411,"phases":770,"primaryCompletion":771,"completion":772,"start":773,"enrollment":16,"conditions":774,"interventions":776},"NCT02688465","Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).",[88],"2017-01","2017-07","2016-09-05",[775],"Parkinson's Disease",[755],{"trials":778,"activeCount":97},[779],{"nctId":780,"briefTitle":781,"status":456,"phases":782,"primaryCompletion":783,"completion":784,"start":785,"enrollment":22,"conditions":786,"interventions":789},"NCT04786158","Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA)",[],"2020-06-01","2020-07-01","2018-12-01",[787,788],"Progressive Supranuclear Palsy","Corticobasal Degeneration",[755],{"intervention":791,"totalTrials":93,"cells":792},"blood sample for genetic test",{"EARLY_PHASE1":793,"PHASE1":795,"PHASE2":797,"PHASE3":799,"PHASE4":801,"NA":803},{"trials":794,"activeCount":97},[],{"trials":796,"activeCount":97},[],{"trials":798,"activeCount":97},[],{"trials":800,"activeCount":97},[],{"trials":802,"activeCount":97},[],{"trials":804,"activeCount":97},[805],{"nctId":806,"briefTitle":807,"status":456,"phases":808,"primaryCompletion":809,"completion":810,"start":811,"enrollment":812,"conditions":813,"interventions":815},"NCT03959605","Genetic Determinant of Foveolar Hypoplasia in Parents of Albinos Children",[],"2021-02-02","2021-10-01","2019-01-06",48,[814],"Albinism, Ocular",[791],{"intervention":817,"totalTrials":93,"cells":818},"Nasopharyngeal swab for RT-PCR SARS-CoV-2",{"EARLY_PHASE1":819,"PHASE1":821,"PHASE2":823,"PHASE3":825,"PHASE4":827,"NA":829},{"trials":820,"activeCount":97},[],{"trials":822,"activeCount":97},[],{"trials":824,"activeCount":97},[],{"trials":826,"activeCount":97},[],{"trials":828,"activeCount":97},[],{"trials":830,"activeCount":97},[831],{"nctId":832,"briefTitle":833,"status":456,"phases":834,"primaryCompletion":835,"completion":836,"start":837,"enrollment":838,"conditions":839,"interventions":842},"NCT05220241","Investigation of the Persistence of SARS-CoV-2 in the Olfactory Mucosa of Patients With Prolonged Symptoms of COVID-19",[89],"2025-06-20","2025-07-10","2022-07-01",51,[840,841],"SARS-CoV-2 Infection","Cognitive Disorder",[817],{"intervention":844,"totalTrials":93,"cells":845},"Alteplase if patient is eligible",{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":852,"PHASE4":854,"NA":856},{"trials":847,"activeCount":97},[],{"trials":849,"activeCount":97},[],{"trials":851,"activeCount":97},[],{"trials":853,"activeCount":97},[],{"trials":855,"activeCount":97},[],{"trials":857,"activeCount":97},[858],{"nctId":859,"briefTitle":860,"status":411,"phases":861,"primaryCompletion":862,"completion":863,"start":864,"enrollment":321,"conditions":865,"interventions":867},"NCT02216565","Embolectomy in Acute SYlvian Thrombosis in Refractory or Ineligible Patients to ALteplase",[89],"2015-08-31","2017-08-24","2014-12-01",[866],"Stroke, Acute",[844],{"intervention":869,"totalTrials":93,"cells":870},"Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies",{"EARLY_PHASE1":871,"PHASE1":873,"PHASE2":875,"PHASE3":877,"PHASE4":879,"NA":881},{"trials":872,"activeCount":97},[],{"trials":874,"activeCount":97},[],{"trials":876,"activeCount":97},[],{"trials":878,"activeCount":97},[],{"trials":880,"activeCount":97},[],{"trials":882,"activeCount":97},[883],{"nctId":884,"briefTitle":885,"status":411,"phases":886,"primaryCompletion":887,"completion":887,"start":888,"enrollment":321,"conditions":889,"interventions":891},"NCT04427254","Study of the Sars-Cov2 Neuroinvasiveness - COVID19",[89],"2022-11-25","2020-06-26",[890],"COVID19",[869],{"intervention":893,"totalTrials":93,"cells":894},"Genetic analysis",{"EARLY_PHASE1":895,"PHASE1":897,"PHASE2":899,"PHASE3":901,"PHASE4":903,"NA":905},{"trials":896,"activeCount":97},[],{"trials":898,"activeCount":97},[],{"trials":900,"activeCount":97},[],{"trials":902,"activeCount":97},[],{"trials":904,"activeCount":97},[],{"trials":906,"activeCount":97},[907],{"nctId":908,"briefTitle":909,"status":456,"phases":910,"primaryCompletion":911,"completion":911,"start":912,"enrollment":913,"conditions":914,"interventions":917},"NCT04658381","Genetic Analysis and Multimodal Retinal Imaging of Asymptomatic Fovea Plana Cases in the General Population",[89],"2023-11-02","2020-12-17",20,[915,916],"Fovea Plana","Albinism",[893],{"intervention":919,"totalTrials":93,"cells":920},"Intravitreal aflibercept",{"EARLY_PHASE1":921,"PHASE1":923,"PHASE2":925,"PHASE3":927,"PHASE4":929,"NA":931},{"trials":922,"activeCount":97},[],{"trials":924,"activeCount":97},[],{"trials":926,"activeCount":97},[],{"trials":928,"activeCount":97},[],{"trials":930,"activeCount":97},[],{"trials":932,"activeCount":97},[933],{"nctId":934,"briefTitle":935,"status":456,"phases":936,"primaryCompletion":937,"completion":937,"start":938,"enrollment":939,"conditions":940,"interventions":942},"NCT02381730","Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment",[89],"2017-08-31","2014-01",37,[941],"Polypoidal Choroidal Vasculopathy",[919],{"intervention":944,"totalTrials":93,"cells":945},"Treatment standardization with aflibercept",{"EARLY_PHASE1":946,"PHASE1":948,"PHASE2":950,"PHASE3":952,"PHASE4":954,"NA":956},{"trials":947,"activeCount":97},[],{"trials":949,"activeCount":97},[],{"trials":951,"activeCount":97},[],{"trials":953,"activeCount":97},[],{"trials":955,"activeCount":97},[],{"trials":957,"activeCount":97},[958],{"nctId":959,"briefTitle":960,"status":456,"phases":961,"primaryCompletion":962,"completion":962,"start":963,"enrollment":484,"conditions":964,"interventions":966},"NCT04793100","Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections",[89],"2025-03-17","2021-03-24",[965],"Central Retinal Vein Occlusion",[944],{"intervention":968,"totalTrials":93,"cells":969},"Botulinum Toxins",{"EARLY_PHASE1":970,"PHASE1":972,"PHASE2":974,"PHASE3":976,"PHASE4":978,"NA":980},{"trials":971,"activeCount":97},[],{"trials":973,"activeCount":97},[],{"trials":975,"activeCount":97},[],{"trials":977,"activeCount":97},[],{"trials":979,"activeCount":97},[],{"trials":981,"activeCount":97},[982],{"nctId":983,"briefTitle":984,"status":456,"phases":985,"primaryCompletion":986,"completion":987,"start":988,"enrollment":989,"conditions":990,"interventions":992},"NCT03363113","Outcome of Botulinum Toxin Treatment for Oromandibular Dystonia",[],"2016-04-01","2016-07-12","2016-01-01",240,[991],"Dystonia; Orofacial",[968],{"intervention":994,"totalTrials":93,"cells":995},"prescription of at least one of the following drugs: rilpivirine, elvitegravir, dolutegravir",{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1002,"PHASE4":1004,"NA":1006},{"trials":997,"activeCount":97},[],{"trials":999,"activeCount":97},[],{"trials":1001,"activeCount":97},[],{"trials":1003,"activeCount":97},[],{"trials":1005,"activeCount":97},[],{"trials":1007,"activeCount":97},[1008],{"nctId":1009,"briefTitle":1010,"status":411,"phases":1011,"primaryCompletion":1012,"completion":1013,"start":1014,"enrollment":93,"conditions":1015,"interventions":1017},"NCT02882230","Evaluation of Neurologic and Psychiatric Adverse Events of Several Antiretroviral Drugs in Real Life Setting",[],"2018-12-03","2019-01-15","2018-11-19",[1016],"HIV",[994],{"intervention":1019,"totalTrials":93,"cells":1020},"Blood samples",{"EARLY_PHASE1":1021,"PHASE1":1023,"PHASE2":1025,"PHASE3":1027,"PHASE4":1029,"NA":1031},{"trials":1022,"activeCount":97},[],{"trials":1024,"activeCount":97},[],{"trials":1026,"activeCount":97},[],{"trials":1028,"activeCount":97},[],{"trials":1030,"activeCount":97},[],{"trials":1032,"activeCount":97},[1033],{"nctId":1034,"briefTitle":1035,"status":456,"phases":1036,"primaryCompletion":1037,"completion":1037,"start":1038,"enrollment":1039,"conditions":1040,"interventions":1043},"NCT03804112","TransIent Perivascular Inflammation of the Carotid Artery (TIPIC) Syndrome: Clinical and Radiological Follow-up",[],"2020-02-18","2018-12-17",47,[1041,1042],"Cervical Pain","Vasculitis",[1019]]